{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-310588","form_type":"8-K","ticker":"SRPT","cik":"0000873303","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2025-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.417443+00:00","generated_at":"2026-05-16T14:09:59.529024+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Sarepta grants CEO Ingram $12M equity awards after 8-year gap","bullets":["CEO Douglas Ingram granted ~$12M total equity: ~$6M time-based RSUs vesting over 3 years and ~$6M performance-based awards tied to Incentive EBITDA for 2026-2027.","Performance awards can pay out 0-200% of target; vesting subject to 3-year service period from Dec 7, 2025.","First equity grant for Ingram since 2017; previously deferred consistent with employment agreement.","Performance condition based on cumulative Incentive EBITDA over two-year period ending Dec 31, 2027.","Up to 269,542 shares at target across four award types (RSUs, units, restricted shares, performance shares)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-310588","json":"https://secwatch.observer/filing/0001193125-25-310588.json","markdown":"https://secwatch.observer/filing/0001193125-25-310588.md","text":"https://secwatch.observer/filing/0001193125-25-310588.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/873303/000119312525310588/0001193125-25-310588-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/873303/000119312525310588/d15497d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T14:09:59.529024+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}